Press Release
Charles River and PathoQuest Strengthen Strategic Partnership

PathoQuest establishes U.S. subsidiary with state-of-the-art biologics genomic testing laboratory in Wayne, PA to expand its next-generation sequencing capabilities.

About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.
To learn more about our unique portfolio and breadth of services, visit www.criver.com.

About PathoQuest
PathoQuest as a pharmaceutical establishment offers biopharmaceutical companies a game-changing Genomic QC testing to secure the biosafety of biological drugs like cell & gene therapy products, vaccines, and recombinant. It enables the ability to reduce the turnaround time for safety testing, replacing traditional methods like animal testing. PathoQuest’s technology combines a Next-Generation Sequencing (NGS) platform with a proprietary sample preparation process completed by proprietary pathogen genome sequence databases and automated analysis pipeline.
Based on its technological platform, PathoQuest has also developed a metagenomic test direct from blood (iDTECT®) to improve the diagnosis of Bloodstream infections and fight against Antimicrobial Resistance (AMR). For more information about PathoQuest, visitwww.pathoquest.com.
Investor Contact for PathoQuest:
Patrick COURT
CFO
finance@pathoquest.com
Media Contact for PathoQuest:
Ophélie PHILIPOT
External Communications Manager
ophelie.philipot@comopi.tech